https://doi.org/10.55788/7d6e19a3
The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor. Particularly in older patients, outcomes of second-line standard-of-care treatment are inferior and often associated with poor health-related quality of life [1,2]. Recently, results from the phase 3 ZUMA-7 trial (NCT03391466) showed significant improvement in event-free survival with axi-cel compared with second-line standard-of-care in patients with relapsed/refractory large B-cell lymphoma [3]. Dr Anna Sureda (University of Barcelona, Spain) presented results on safety, efficacy, and patient-reported outcomes in a pre-planned subgroup analysis of ZUMA-7 of patients aged ≥65 years [4].
A total of 109 patients enrolled in ZUMA-7 were aged 65 years or older (median age 70 years); 51 participants were allocated to the axi-cel arm, 58 participants were allocated to the standard-of-care arm (i.e. high-dose chemotherapy plus stem cell transplantation). Compared with standard-of-care patients, more axi-cel patients had high-risk features at baseline.
The median event-free survival (primary endpoint in ZUMA-7) was 21.5 months in the axi-cel arm and 2.5 months in the standard-of-care arm (HR 0.276; P<0.0001). Objective response rate was 88% (75% complete response) in the axi-cel arm and 52% (33% complete response) in the standard-of-care arm. The overall survival rate at 2 years was 64% in the axi-cel arm versus 51% in the standard-of-care arm. Of note, 57% of patients in the standard-of-care arm received subsequent cellular immunotherapy (of protocol).
The safety profile of axi-cel was manageable and consistent with previous studies in refractory large B-cell lymphoma. Cytokine-release syndrome grade ≥3 was observed in 4 (8%) patients in the axi-cel arm (median duration 8 days). In the quality-of-life analysis set (axi-cel n=46; standard-of-care n=42), a clinically meaningful difference in quality-of-life scores was observed in favour of axi-cel from day 100 to 150, suggesting a faster recovery to pre-treatment quality-of-life.
“This data demonstrates that older patients with relapsed/refractory large B-cell lymphoma, who are frequently considered transplant-ineligible based on age, can safely receive second-line curative intent therapy,” concluded Dr Sureda.
- Di M, et al. Oncologist. 2021;26:120–132.
- Oerlemans S, et al. Ann Hematol 2014;93:1705–1715.
- Locke FL, et al. N Engl J Med 2022;386:640–654.
- Sureda A, et al. Clinical and patient-reported outcomes in a phase 3 study of axicabtagene ciloleucel (AXI-CEL) vs standard-of-care in elderly patients with relapsed/refractory large B-cell lymphoma (ZUMA-7). Abstract S211. EHA2022 Hybrid Congress, 09–12 June.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD1 treatment Next Article
Triple-therapy improves PFS in fit, previously untreated CLL »
« Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD1 treatment Next Article
Triple-therapy improves PFS in fit, previously untreated CLL »
Table of Contents: EHA 2022
Featured articles
Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma
AML
Pan-clonal score predicts first-line treatment response in AML
Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML
No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics
Lymphocytic Leukaemia & Lymphoma
New subtypes of oncogenic deregulation in childhood T-ALL
Triple-therapy improves PFS in fit, previously untreated CLL
Axi-cel superior to standard-of-care in older patients with relapsed/refractory large B-cell lymphoma
Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD1 treatment
DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in high-risk Burkitt lymphoma
Myeloma
Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma
Triplet therapy plus early ASCT improves PFS in newly diagnosed multiple myeloma versus triplet therapy alone
Non-Cancerous Blood Disorders
Momelotinib induces a rapid and sustained improvement in haemoglobin levels in patients with myelofibrosis
Caplacizumab is safe and effective in patients with iTTP, also in the long term
Transfusion-dependent β-thalassaemia patients continue to benefit from luspatercept after 3 years of treatment
Single-dosed exa-cel leads to early and durable increase of foetal haemoglobin
PI3Kδ inhibitor leniolisib improves symptoms in patients with APDS/PASLI
Related Articles
December 4, 2018
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy